Insulet stock (US45784P1012): Q1 2026 earnings beat and next report date in focus
02.06.2026 - 22:30:19 | ad-hoc-news.de
Insulet shares on Nasdaq in the United States remain in focus after the diabetes technology group reported an earnings beat for Q1 2026 in early May and market participants now look ahead to the expected Q2 2026 update later this summer, keeping the stock in the spotlight among U.S. medical device names, according to MarketBeat as of 06/02/2026.
According to MarketBeat, Insulet reported Q1 2026 earnings per share of USD 1.42 on 05/06/2026, topping the consensus estimate of USD 1.19 by USD 0.23 and underlining operating momentum in its insulin delivery franchise on the Nasdaq-listed name trading under ticker PODD.
MarketBeat data as of 06/02/2026 also indicate that Insulet has not yet confirmed the exact date for its next earnings release, but based on its historical reporting pattern the estimated date for the Q2 2026 report is 08/06/2026, which investors in the United States and beyond are watching as a potential next catalyst for the stock.
For investors following U.S.-listed medical technology stocks, the combination of a Q1 2026 earnings beat and an upcoming expected Q2 2026 date gives Insulet a defined fundamental timetable even though no updated full-year 2026 guidance has been highlighted in the MarketBeat overview.
As of: 06/02/2026
By the editorial team - specialized in equity coverage.
At a glance
- Name: Insulet
- Sector/industry: Medical devices, diabetes care technology
- Headquarters/country: Acton, United States
- Core markets: United States, Canada, Europe and select international regions
- Key revenue drivers: Wearable insulin delivery systems and related supplies
- Home exchange/listing venue: Nasdaq (PODD)
- Trading currency: USD
Insulet: core business model
Insulet focuses on developing and commercializing tubeless insulin delivery systems and related digital tools, with revenue largely deriving from ongoing use of its wearable insulin pumps and associated consumables by people living with diabetes.
Latest quarterly results for Insulet at a glance
Insulet’s most recent reported figures relate to Q1 2026, when the company delivered earnings per share of USD 1.42, compared with analyst expectations of USD 1.19, based on MarketBeat data referencing the company’s 05/06/2026 disclosure.
While MarketBeat’s earnings calendar as of 06/02/2026 shows no formally confirmed date for the next release, it flags an estimated Q2 2026 earnings date of 08/06/2026 by extrapolating from last year’s reporting schedule, giving investors an indicative timeline for when fresh revenue and profitability metrics may be available.
Read more
Additional news and developments on the stock can be explored via the linked overview pages.
Sentiment and reactions on Insulet
Following the Q1 2026 earnings beat and ahead of the expected Q2 2026 update, social media and video platforms continue to host active discussions among traders and patients about Insulet’s growth prospects and product adoption trends.
Conclusion
Insulet’s Q1 2026 earnings performance, with EPS of USD 1.42 versus a consensus of USD 1.19, positions the Nasdaq-listed U.S. medical device group as a closely watched name within diabetes technology going into the second half of the year.
With an estimated Q2 2026 earnings date of 08/06/2026 based on historical patterns but not yet formally confirmed, the next set of quarterly figures could provide further detail on how the company is balancing growth in its insulin delivery franchise with profitability.
Disclaimer: This article does not constitute investment advice. The comprehensive scope of this informative article was made possible through the use of a.i.. Stocks are volatile financial instruments.
